Score Overview
Explore the 2021 public Archive ranking →
Where Haemonetics Corporation has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- HAE
2002: 74.1% · 2021: 72.0% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 105.80 | — |
1 Year2025-09-29 | $ 48.12 | 119.87% |
5 Years2021-09-29 | $ 70.46 | 50.16% |
10 Years2016-09-29 | $ 35.71 | 196.28% |
20 Years2006-09-29 | $ 23.40 | 352.14% |
30 Years1996-09-27 | $ 10.56 | 10x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | 30 Years1996-09-27 |
|---|---|---|---|---|---|---|
| Price | $ 105.80 | $ 48.12 | $ 70.46 | $ 35.71 | $ 23.40 | $ 10.56 |
| Return | — | 119.87% | 50.16% | 196.28% | 352.14% | 10x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 1.35B | $ 96M | $ 223M |
| 2026 | $ 1.33B | $ 97M | $ 245M |
| 2025 | $ 1.36B | $ 167M | $ 306M |
| 2024 | $ 1.30B | $ 117M | $ 178M |
| 2023 | $ 1.16B | $ 115M | $ 284M |
| 2022 | $ 993M | $ 43M | $ 259M |
| 2021 | $ 870M | $ 79M | $ 192M |
| 2020 | $ 988M | $ 76M | $ 137M |
| 2019 | $ 967M | $ 55M | $ 169M |
| 2018 | $ 903M | $ 45M | $ 180M |
| 2017 | $ 886M | -$ 26M | $ 139M |
| 2016 | $ 908M | -$ 55M | $ 115M |
| 2015 | $ 910M | $ 16M | $ 160M |
| 2014 | $ 938M | $ 35M | $ 192M |
| 2013 | $ 891M | $ 38M | $ 179M |
| 2012 | $ 727M | $ 66M | $ 228M |
| 2011 | $ 676M | $ 79M | $ 196M |
| 2010 | $ 645M | $ 58M | $ 141M |
| 2009 | $ 597M | $ 59M | $ 156M |
| 2008 | $ 516M | $ 51M | $ 133M |
| 2007 | $ 449M | $ 49M | $ 229M |
| 2006 | $ 419M | $ 69M | $ 250M |
| 2005 | $ 383M | $ 39M | $ 185M |
| 2004 | $ 364M | $ 29M | $ 118M |
| 2003 | $ 336M | $ 28M | $ 49M |
| 2002 | $ 319M | $ 30M | $ 67M |
| 2001 | $ 293M | $ 7M | $ 74M |
| 2000 | $ 277M | $ 18M | $ 61M |
| 1999 | $ 282M | $ 21M | $ 56M |
| 1998 | $ 285M | -$ 24M | $ 21M |
| 1997 | $ 309M | $ 33M | $ 8M |
| 1996 | $ 278M | $ 35M | $ 13M |
| 1995 | $ 262M | $ 33M | $ 4M |
| 1994 | $ 248M | $ 31M | $ 16M |
| 1993 | $ 216M | $ 24M | $ 10M |
| 1992 | $ 176M | $ 18M | $ 2M |
Haemonetics Corporation fundamental performance
Between 2021 and 2026, revenue grew from $ 870M to $ 1.33B and net income grew from $ 79M to $ 97M. Revenue increased in 4 of those 5 years; net income in 3.
Between 2016 and 2026, revenue grew from $ 908M to $ 1.33B and net income went from -$ 55M to $ 97M. Revenue increased in 8 of those 10 years; net income in 7.
Haemonetics Corporation currently holds a 20-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.
Membership
Continue HAE’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
